|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Instituto Rosenbusch S.A.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Instituto Rosenbusch S.A. Headquarters San Jose 1481; Buenos Aires (City); Federal Capital |
Status: Listed Legal Form: Limited Liability Partnership Operational Status: Operational Fiscal ID (CUIT): 30501407093 Fiscal ID (ISIN CODE ): ARROSE010017 Financial Auditors: Estudio Silvari (2011) Total Employees: 75 Tel: +54 11 4304 0051 |
|
Company Description |
| The Institute Rosenbusch S.A. is a company created with Argentine capitals. The company is divided in 3 principal areas: Industry, Marketing, Administration and Finance. Rosenbusch occupies a leadership position on the veterinary market with a great participation in different market sectors. The commercial structure covers the whole country. Its commercial activity, dedicated exclusively to the animal health and based on the participation of veterinary doctors all over the country, has placed Rosenbusch, | ||
|
||
Company Analysis |
| According to the Consolidated - Audited financial statement for the Year of 2011, total net operating revenues increased with 26.50%, from ARS 56,880,189 to ARS 71,952,103 . Operating result increased from ARS 2,950,858 to ARS 5,755,505 which means 95.05% change. The results of the period increased 95.05% reaching ARS 5,755,505 at the end of the period against ARS 2,950,858 last year. Return on equity (Net income/Total equity) went from 6.02% to 10.56%, the Return On Asset (Net income / Total Asset) went from 4.02% to 6.62% and the Net Profit Margin (Net Income/Net Sales) went from 5.19% to 8.00% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 56.30% compared to 47.42% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 2.77 to 2.38 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Y (non-cons) |
2012 Q3C (cons) |
|
 | ||
| Audited | Audited | |
| ||
| BCBA - EEFF IFRS | BCBA - EEFF IFRS | |
| ||
| Unit | 1 | 1 |
| ||
Balance Sheet
| ||
Total Assets |
109,283,992 |
96,300,659 |
| ||
Current Assets |
62,436,722 |
76,653,112 |
| ||
Total Liabilities |
45,427,074 |
33,552,317 |
| ||
Shareholders Equity |
63,856,918 |
62,748,342 |
| ||
Current Liabilities |
27,215,917 |
27,381,911 |
| ||
| * All the accounts are in ARS. | ||
Income Statement
| ||
Total Operating Revenue |
54,849,591 |
55,616,511 |
| ||
Operational Profit (Loss) |
3,328,271 |
3,279,034 |
| ||
| * All the accounts are in ARS. | ||
 |